Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,877 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05656794RecruitingPhase 2
Radiation after treatment for prostate cancer that has spread
This trial studies whether adding a targeted course of radiation to the prostate area after initial systemic treatment can improve outcomes for people with metastatic prostate cancer. It may help control the cancer by treating remaining disease after medicines have started working.
Toronto, OntarioAges 18–100 - NCT05257993RecruitingPhase 1/Phase 2
Pancreatic cancer trial testing JPI-547 with standard chemo
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
Gyeonggi-doAges 19–79 - NCT06576635Recruiting
Chemotherapy study for advanced lung cancer
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
Chicago, IllinoisAges 18 years+ - NCT07296341RecruitingPhase 1/Phase 2
HRS-4642 plus other therapies for pancreatic cancer
This study tests an experimental drug (HRS-4642) combined with other cancer treatments for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07204574RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer after first treatment
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
TaoyuanAges 18 years+ - NCT06642844RecruitingPhase 3
Bevacizumab dose adjustment for colorectal cancer
This trial tests whether adjusting the dose of bevacizumab based on your blood levels can improve first-line treatment for metastatic colorectal cancer that can't be removed with surgery.
BesançonAges 18–99 - NCT04794075Recruiting
Nursing and education support for women on hormone breast therapy
This trial tests a structured nursing and education program to support people with non-metastatic breast cancer who take hormone-blocking treatment. It may help you manage side effects and stay supported during follow-up, using online questionnaires and scheduled sessions.
Bourg-en-BresseAges 18–75 - NCT06321081RecruitingPhase 2
Rechallenge combo for metastatic colorectal cancer
This trial tests a combination of three drugs (cetuximab, irinotecan, and envafolimab) as a ‘rechallenge’ – meaning if you had good results with cetuximab or irinotecan before, trying them again with a new drug might help shrink or control your cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07686835RecruitingPhase 2
High-fiber diet to help immunotherapy work better in advanced melanoma
This trial tests if adding extra dietary fiber before and during immunotherapy can change gut bacteria to make the treatment more effective. It is for people with advanced melanoma who are about to start their first immunotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Glendale, ArizonaAges 18 years+ - NCT03758976Recruiting
Study of scans in advanced breast cancer recurrence
This study looks at people with advanced breast cancer to better understand recurrence by using information from recent scans. It may help researchers improve how advanced disease is assessed and followed over time.
LundAges 18 years+ - NCT04951817Recruiting
PSMA PET/CT scan to assess Ra-223 treatment in advanced prostate cancer
This trial studies whether a special whole-body scan (PSMA PET/CT) can help assess how well Ra-223 (a targeted treatment) may work in men with advanced prostate cancer that has spread to the bones. It may help doctors choose and plan Ra-223 treatment more effectively.
Taoyuan CityAges 40–85 - NCT05229003RecruitingPhase 2
Irinotecan, anlotinib, and pembrolizumab-like drug for advanced colon cancer
This Phase 2 study tests adding anlotinib and penpulimab to irinotecan for colorectal cancer that has come back or spread after earlier chemotherapy. It may help shrink tumors and control the disease when standard first-line treatment no longer works.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT05277935Recruiting
Wearable activity tracking for hormone-positive metastatic breast cancer
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
Rio de JaneiroAges 18 years+ - NCT05310643RecruitingPhase 2
Nivolumab and ipilimumab for bowel cancer resistant to anti-PD1
This Phase 2 study tests two immunotherapy medicines (nivolumab and ipilimumab) in people with metastatic colorectal cancer that has not responded to anti-PD1 treatment. It focuses on tumors with mismatch repair problems (dMMR) and/or high microsatellite instability (MSI).
BesançonAges 18 years+ - NCT05351502RecruitingPhase 1
Nitric oxide injection for solid tumors that can’t be removed
This Phase 1 study tests whether injecting nitric oxide into certain solid tumors is safe and may help shrink tumors that cannot be removed with surgery. It includes adults with measurable, treatment-resistant skin or under-skin (cutaneous or subcutaneous) tumors and checks for side effects and early signs of benefit.
BeershebaAges 18 years+ - NCT05577689Recruiting
New treatment target study for metastatic prostate cancer
This trial studies a new therapy target for people with prostate cancer that has spread to other parts of the body. You may be a candidate if you can provide a cancer tissue sample and are able to consent to the study.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05693766RecruitingPhase 2
Gene test guides treatment for hormone-positive breast cancer
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
Birmingham, AlabamaAges 18 years+ - NCT05787197Recruiting
Blood test to guide treatment after colon cancer liver surgery
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
BesançonAges 18 years+ - NCT05970705RecruitingPhase 2
Regorafenib plus TAS-102 versus regorafenib alone for advanced bowel cancer
This Phase 2 study tests whether adding TAS-102 to regorafenib works better than regorafenib by itself for metastatic colorectal cancer after at least one prior treatment has stopped working. It aims to improve how long the cancer can be controlled for patients in later treatment lines.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06177015RecruitingPhase 3
Darolutamide with chemo for metastatic prostate cancer
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Nanjing, JiangsuAges 40–80 - NCT06195709RecruitingPhase 3
Study of PET imaging and blood tests for ER+ HER2- metastatic breast cancer
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
BayonneAges 18 years+ - NCT06208397Recruiting
MRI study to understand liver tumor growth patterns
This trial uses MRI scans to study how colorectal cancer that has spread to the liver grows. It may help doctors choose better treatments.
Shenyang, LiaoningAges 18–80 - NCT06226857RecruitingPhase 3
Anti-EGFR for left-sided, RAS wild-type metastatic colorectal cancer
This trial tests whether anti-EGFR therapy works better for people with left-sided colorectal cancer that has spread, whose tumors do not have certain gene mutations (RAS wild-type). It is for those who have not yet had treatment for metastatic disease.
MoscowAges 18–99
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,877 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.